Literature DB >> 27864098

Screening for mucopolysaccharidoses in the Turkish population: Analytical and clinical performance of an age-range specific, dye-based, urinary glycosaminoglycan assay.

Khaled El Moustafa1, Serap Sivri2, Sevilay Karahan3, Turgay Coşkun2, Filiz Akbıyık1, İncilay Lay4.   

Abstract

Comprehensive analytical and diagnostic performance of urinary quantitative GAG analysis with dimethylmethylene blue (DMB) and the age-specific reference ranges were determined in Turkish population, which has a high incidence of MPSs. Precision, linearity, recovery and accuracy/trueness, limits, stability, and effect of interferents were tested according to CLSI guideline. Clinical performance was evaluated with ROC analyses including 45 MPS patients. Intra-day and inter-day precisions were <5% and <11% (CV), respectively. LoD was 9.12mg/L and LoQ was 23.3mg/L. The highest reference values for urinary GAG excretion were determined in an age-specific manner. In the 2-13years age cohort, a cut-off of 89.86mg/g creatinine resulted in 98.07% sensitivity and 93.33% specificity. Proteinuria and hematuria interfered with analysis in some instances. Neither leukocyturia nor pH changes affected the assay. Stability analysis indicated that freezing urine samples for transfer is unnecessary. Of the 45 MPS patient samples evaluated, only three tested negative including MPS II, IVA and VI. Despite limitations due to low levels of urinary GAG excretion in some cases, urinary GAG analysis with DMB with its technical simplicity, low cost, and precise quantitative results, is a valuable screening method, particularly in populations with a high rate of MPSs.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  1,9-Dimethylene blue; Mucopolysaccharidoses; Reference intervals; Screening MPSs; Urinary glycosaminoglycan assay; Validation

Mesh:

Substances:

Year:  2016        PMID: 27864098     DOI: 10.1016/j.cca.2016.11.015

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study.

Authors:  Cristóbal Colón; J Victor Alvarez; Cristina Castaño; Luís G Gutierrez-Solana; Ana M Marquez; María O'Callaghan; Félix Sánchez-Valverde; Carmen Yeste; María-Luz Couce
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 2.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10

3.  Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency.

Authors:  Sarah Verheyen; Jasmin Blatterer; Michael R Speicher; Gandham SriLakshmi Bhavani; Geert-Jan Boons; Mai-Britt Ilse; Dominik Andrae; Jens Sproß; Frédéric Maxime Vaz; Susanne G Kircher; Laura Posch-Pertl; Daniela Baumgartner; Torben Lübke; Hitesh Shah; Ali Al Kaissi; Katta M Girisha; Barbara Plecko
Journal:  J Med Genet       Date:  2021-12-16       Impact factor: 5.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.